Abituzumab

Abituzumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	CD51
Clinical data
ATC code	none;
Identifiers
CAS Number	1105038-73-0;
ChemSpider	none;
UNII	724QD330RD;

Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer.^[1]^[2]

^ EP 2706358, Behrens J, "Biomarkers for inhibitors with anti-angiogenic activity", published 12 March 2014, assigned to Merck Patent GmbH
^ Hussain M, Le Moulec S, Gimmi C, Bruns R, Straub J, Miller K (July 2016). "Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer". Clinical Cancer Research. 22 (13): 3192–200. doi:10.1158/1078-0432.CCR-15-2512. PMID 26839144.

[EP2706358-1] EP 2706358, Behrens J, "Biomarkers for inhibitors with anti-angiogenic activity", published 12 March 2014, assigned to Merck Patent GmbH

[Hussain_2016-2] Hussain M, Le Moulec S, Gimmi C, Bruns R, Straub J, Miller K (July 2016). "Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer". Clinical Cancer Research. 22 (13): 3192–200. doi:10.1158/1078-0432.CCR-15-2512. PMID 26839144.

[1]

[2]